clinical trial retatrutide Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and Lilly Prepares for Retatrutide FDA

Not every person requires, wants, needs, or should have weight loss at these high numbers. Heres what doctors want you to know about who could benefit from retatrutide and when a different drug might be better

Microdosing GLP-1 (contains semaglutide): $250/month Microdosing GIP (contains tirzepatide): $340/month All dosages for each medication are the same cost with our flat fee pricing

In addition to GLP-1s, the startup offers weight-management medications including metformin

CAS Number 2381089-83-2 Molecular Formula C221H342N46O68 Molecular Weight 4731.4 g/mol Half-Life ~6 days (research reports) Sources & References Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Jastreboff AM, et al

Energy restriction reduces fractional calcium absorption in mature obese and lean rats